Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post Market Clinical Follow-Up KeriFuse®

NCT: NCT06546332 · ACTIVE_NOT_RECRUITING

NCT IDNCT06546332
StatusACTIVE_NOT_RECRUITING
Start Date2022-07-05
Completion2027-03
SponsorKeri Medical SA (INDUSTRY)
First posted
Last updated

Brief Summary

The general objective of this study is to evaluate the performances and the safety related to the KeriFuse® intramedullary arthrodesis implant and associated instrumentation used in accordance with their approved labelling and instruction for use. Performance and safety of KeriFuse® intramedullary arthrodesis implant will be established on short and middle-terms in regards to the implant life-cycle.

Frequently Asked Questions

What is Post Market Clinical Follow-Up KeriFuse®?

Post Market Clinical Follow-Up KeriFuse® is a clinical trial registered under NCT06546332. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06546332?

The current status of NCT06546332 (Post Market Clinical Follow-Up KeriFuse®) is: ACTIVE_NOT_RECRUITING.

When did Post Market Clinical Follow-Up KeriFuse® start?

Post Market Clinical Follow-Up KeriFuse® started on 2022-07-05.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.